Bailard, Inc. Exact Sciences Corp Transaction History

Bailard, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	BUY	$65.94 - $99.04 $230,987 - $346,937	3,503 New	3,503 $238,000
Q1 2023 May 08, 2023	BUY	$47.19 - $70.77 $145,911 - $218,820	3,092 New	3,092 $209,000
Q2 2022 Jul 27, 2022	SELL	$35.61 - $76.23 $518,374 - $1.11 Million	-14,557 Closed	0 $0
Q1 2022 Apr 25, 2022	SELL	$57.56 - $82.54 $19,570 - $28,063	-340 Reduced 2.28%	14,557 $1.02 Million
Q2 2021 Aug 13, 2021	SELL	$93.66 - $139.27 $62,190 - $92,475	-664 Reduced 4.27%	14,897 $1.85 Million
Q1 2021 May 13, 2021	BUY	$116.57 - $155.01 $1.45 Million - $1.93 Million	12,469 Added 403.27%	15,561 $2.05 Million
Q2 2020 Aug 12, 2020	BUY	$55.75 - $92.75 $172,379 - $286,783	3,092 New	3,092 $269,000
Q1 2020 Apr 16, 2020	SELL	$37.9 - $104.44 $117,186 - $322,928	-3,092 Closed	0 $0
Q4 2019 Jan 31, 2020	SELL	$77.66 - $99.74 $86,047 - $110,511	-1,108 Reduced 26.38%	3,092 $286,000
Q3 2018 Nov 13, 2018	BUY	$48.29 - $80.6 $202,818 - $338,520	4,200 New	4,200 $331,000

673

162M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.2B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.